mitemcinal

Mitemcinal is a small molecule, orally administered prokinetic agent derived from the macrolide antibiotic erythromycin. It acts as an agonist at the motilin receptor (also known as GPR38), stimulating and promoting peristalsis in the stomach and other segments of the gastrointestinal tract. Unlike erythromycin, mitemcinal lacks antibiotic properties but retains strong promotility effects, making it a candidate for long-term treatment of gastrointestinal motility disorders without contributing to antibiotic resistance. It was primarily developed for conditions such as gastroparesis (including diabetic gastroparesis), gastroesophageal reflux disease, non-ulcer dyspepsia, and irritable bowel syndrome. Clinical development reached phase II trials; however, due to lack of significant efficacy over placebo in key studies—particularly in diabetic gastroparesis—further development was discontinued[1][2][3][4][5][6].

Brand names

Mitemcinal-Fumarate

Other names

mitemcinalMitemcinal [INN]3'-N-dimethyl-11-deoxy-3'-N-isopropyl-12-O-methyl-11-oxo-8,9-didehydroerythromycinMitemcinal fumarate (USAN)UNII-6X5NRJ664LUNII6X5NRJ664LUNII 6X5NRJ664L154738–42–8